GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Arbutus Biopharma
Arbutus Biopharma is a biotech company focused on treating hepatitis B. Its stock price is also heavily dependent on its patent portfolio related to mRNA delivery technology, which has led to legal disputes with Moderna and is reflected in its share price.
Share prices of companies in the market segment - Pharma liver
Arbutus Biopharma (ABUS) is a biopharmaceutical company focused on developing drugs for the treatment of chronic hepatitis B, a serious liver disease. We have classified it in the Pharmaceuticals/Liver Diseases segment. The chart below shows the dynamics of this highly specialized biotech sector.
Broad Market Index - GURU.Markets
Arbutus Biopharma is a biopharmaceutical company developing drugs to treat chronic hepatitis B. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Arbutus shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ABUS - Daily change in the company's share price Arbutus Biopharma
Shares of Arbutus Biopharma, a company developing hepatitis B drugs, are experiencing extreme volatility. Change_co measures market reaction to clinical trial data and patent disputes. This metric is a critical component of System.GURU.Markets' formulas that assess binary risks in biotech.
Daily change in the price of a set of shares in a market segment - Pharma liver
Arbutus Biopharma Corporation is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ABUS, which focuses on hepatitis B treatment, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Arbutus is a biopharmaceutical company specializing in hepatitis B treatments. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Arbutus's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Arbutus Biopharma
Arbutus is a biopharmaceutical company specializing in the treatment of liver diseases. Its year-over-year performance has been extremely volatile, reflecting both clinical trial successes and failures, as well as patent disputes, typical of this high-risk strategy.
Annual dynamics of market capitalization of the market segment - Pharma liver
Arbutus Biopharma Corp. is a biotechnology company specializing in the development of drugs for the treatment of hepatitis B. It also holds important patents on mRNA delivery systems. The chart below shows how the market values its scientific potential and revenue from licensing its intellectual property.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Arbutus is a biotech company whose stock performance is driven not only by its scientific developments but also by its patent portfolio, which is key to mRNA technologies. The chart tells a complex story, intertwining science, legal issues, and expectations from licensing agreements with pharmaceutical giants.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Arbutus Biopharma
The market capitalization of Arbutus, a biopharmaceutical company, depends on its R&D cycle and litigation. Monthly fluctuations on the chart reflect news about clinical trials of its hepatitis B drugs, as well as patent disputes with Moderna, which could yield significant royalties.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Arbutus Biopharma is a biotech company focused on finding a cure for chronic hepatitis B. Its market cap reflects investors' bets on the success of its research and future patents. The chart below reflects the overall sentiment in the liver disease biotech industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Arbutus Biopharma is a biotech company developing treatments for hepatitis B and COVID-19. Its value is tied to its intellectual property and the success of its clinical programs. Its stock price is driven by laboratory and court news, rather than macroeconomic factors that impact the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Arbutus Biopharma
Shares of Arbutus Biopharma, which focuses on hepatitis B treatment, exhibit the high weekly volatility typical of biotech. News about clinical trials, patent litigation (especially with Moderna), and competitor actions cause sharp price movements.
Weekly dynamics of market capitalization of the market segment - Pharma liver
Arbutus Biopharma shares, like the entire biotech sector, are highly dependent on overall investor risk sentiment. Regulatory news and scientific breakthroughs in hepatitis B treatment could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Arbutus Biopharma, like many biotech companies, can exhibit dynamics completely unrelated to the market. News about patent disputes or clinical trials are more important to the company than the state of the economy. The chart will reveal these moments of "living in its own world."
Market capitalization of the company, segment and market as a whole
ABUS - Market capitalization of the company Arbutus Biopharma
The Arbutus Biopharma market capitalization chart represents the financial valuation of a biotech company engaged in a decades-long battle to develop a cure for chronic hepatitis B. It also reflects the value of its patent portfolio for RNA drug delivery technologies. Its dynamics represent a complex history of scientific research and legal battles with giants like Moderna.
ABUS - Share of the company's market capitalization Arbutus Biopharma within the market segment - Pharma liver
Arbutus Biopharma is a biotech company focused on developing a cure for chronic hepatitis B. Its market share is based on this ambitious goal. The chart shows how the market values its scientific progress and extensive patent portfolio for RNA drug delivery technology.
Market capitalization of the market segment - Pharma liver
Arbutus Biopharma is focused on finding a cure for chronic hepatitis B. The chart below shows the overall market capitalization of the sector. Its dynamics reflect the enormous hopes for a cure for this global disease. Arbutus is a prominent participant in this challenging scientific race.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotech companies visible on the chart are battling diseases like hepatitis B. Arbutus Biopharma is developing drugs to treat this chronic condition. Its market cap is a risky bet on its research and development, as well as revenue from licensing its RNA delivery technologies.
Book value capitalization of the company, segment and market as a whole
ABUS - Book value capitalization of the company Arbutus Biopharma
Arbutus Biopharma's chart represents capital for the search for a cure for hepatitis B. The company's R&D-stage book value consists of financial reserves and valuable patents for RNA delivery technology. These assets are aimed at developing a functional cure for chronic viral infection.
ABUS - Share of the company's book capitalization Arbutus Biopharma within the market segment - Pharma liver
Arbutus Biopharma, a biotech company focused on hepatitis B treatment, has R&D assets. Its share in the sector reflects investments in laboratories and scientific equipment. The company's current value lies in its intellectual property and clinical development.
Market segment balance sheet capitalization - Pharma liver
Arbutus Biopharma is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Arbutus focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Arbutus Biopharma is a biotechnology company focused on developing a cure for chronic hepatitis B. Its book value comes from R&D capital and a valuable portfolio of patents for its drug delivery technology (LNP), which it licenses to other pharmaceutical companies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Arbutus Biopharma
Arbutus Biopharma is a biotech company. Its market capitalization is a premium to its cash flow, reflecting not only the promise of its own drugs but also the value of its patent portfolio, which it licenses to other companies.
Market to book capitalization ratio in a market segment - Pharma liver
Arbutus Biopharma is focused on developing a drug to treat chronic hepatitis B. Like many biotech companies, its value is determined by the potential of its scientific developments. The chart shows the premium investors place on its scientific approach and patents compared to its current tangible assets.
Market to book capitalization ratio for the market as a whole
Arbutus Biopharma is a biotechnology company focused on developing a treatment for chronic hepatitis B. It also holds important patents for RNA drug delivery technology. Its market valuation reflects both the potential of its own developments and potential royalties from other companies.
Debts of the company, segment and market as a whole
ABUS - Company debts Arbutus Biopharma
Arbutus Biopharma is a biotech company focused on developing a cure for chronic hepatitis B. Developing antiviral drugs is a lengthy and expensive process. This chart shows how the company manages its capital, raising funds to fund its research and clinical trials on the path to creating an effective therapy.
Market segment debts - Pharma liver
Arbutus Biopharma is a biotechnology company focused on developing a cure for hepatitis B. It also holds important patents for RNA drug delivery systems. Its R&D funding relies on partnership fees and equity raising. This chart reflects its financial position.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Arbutus Biopharma
Arbutus Biopharma is a biotech company focused on treating hepatitis B. This chart shows its financial structure. For a company in clinical development, whose future depends on the success of scientific research, debt is a significant risk. It shows how dependent the company is on external financing to continue its operations.
Market segment debt to market segment book capitalization - Pharma liver
Arbutus Biopharma is focused on developing a cure for chronic hepatitis B. Biotech research into viral diseases requires long-term financing. This chart shows the overall debt burden in the pharmaceutical industry. It provides context for understanding how Arbutus raises capital for its multi-year, risky clinical trials.
Debt to book value of all companies in the market
Arbutus Biopharma Corp. is a biopharmaceutical company working on a treatment for hepatitis B. Being in clinical development, it incurs significant R&D expenses. This chart illustrates that, in the current environment, equity capital is virtually the only source of financing for such companies, as the debt market is inaccessible.
P/E of the company, segment and market as a whole
P/E - Arbutus Biopharma
This chart shows the valuation of Arbutus Biopharma, a biotech focused on treating hepatitis B. The company doesn't have stable profits, so the P/E ratio isn't relevant. Its value is determined by the potential of its scientific developments, as well as the value of its patent portfolio, which is licensed to other companies.
P/E of the market segment - Pharma liver
Arbutus Biopharma is a biopharmaceutical company focused on developing drugs to treat chronic hepatitis B. This chart shows the average valuation for the sector, providing investors with context for assessing the scientific potential and risks associated with developing drugs to treat liver diseases.
P/E of the market as a whole
Arbutus Biopharma is a biotech company focused on developing a cure for hepatitis B. It also holds important patents on RNA delivery technology used in vaccines. Its valuation is a combination of its own drug pipeline and potential royalties from other companies. It is not correlated with the overall economic trends shown in this chart.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Arbutus Biopharma
Arbutus Biopharma is a biopharmaceutical company focused on developing a cure for chronic hepatitis B. Its value is determined by the potential of this breakthrough therapy. This chart reflects investors' confidence in the company's scientific platform and the likelihood of clinical trial success, which underpins future revenue projections.
%20P%2FE%20Arbutus%20Biopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Arbutus-Biopharma&v=1772624454026 "Chart of the company's future (projected) P/E Arbutus Biopharma")
Future (projected) P/E of the market segment - Pharma liver
Arbutus Biopharma is a biopharmaceutical company focused on developing a treatment for chronic hepatitis B. This chart shows general expectations for the biotech sector. ABUS's position relative to the average reflects investor confidence in its scientific platform, including its RNA delivery technology, and the potential to create a functional cure for this disease.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772624454066 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Arbutus Biopharma is a biotech company working on a cure for hepatitis B and other viral diseases. Like many companies in this field, its value is based on the potential of its research and development. This overall risk appetite chart shows how willing the market is to invest in long-term, risky biotech plays.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624454113 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Arbutus Biopharma
Arbutus Biopharma is a biotechnology company focused on developing drugs for the treatment of chronic hepatitis B. Its current financial structure consists of clinical trial expenses and revenue from licensing agreements. Future profitability depends on the success of its drug candidates.
Profit of companies in the market segment - Pharma liver
Arbutus Biopharma is a biopharmaceutical company focused on developing a cure for chronic hepatitis B. Its future depends on the success of its clinical programs and partnerships. This chart shows the overall profitability of its segment. It reflects the overall progress of the industry in treating viral liver diseases and the investment attractiveness of this area.
Overall market profit
Arbutus Biopharma is a biotech company focused on developing a cure for chronic hepatitis B. Its value is determined by progress in clinical trials. The overall economic situation, reflected in this chart, is of secondary importance but impacts the investment climate and the company's ability to raise capital to continue its research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Arbutus Biopharma
Arbutus Biopharma is focused on developing a treatment for chronic hepatitis B. The company's future revenue is entirely dependent on the success of its clinical programs and potential partnerships. This chart reflects analysts' speculative expectations regarding the scientific breakthrough and commercial potential of its developments in this complex area.
%20profit%20of%20the%20company%20Arbutus%20Biopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Arbutus-Biopharma&v=1772624454330 "Graph of future (projected) profit of the company Arbutus Biopharma")
Future (predicted) profit of companies in the market segment - Pharma liver
Arbutus Biopharma is developing drugs to treat chronic hepatitis B, striving to create a functional cure. The company's future depends entirely on the success of its clinical programs and scientific breakthroughs. This chart reflects forecasts for the entire biotech sector, helping to assess Arbutus' potential to address one of the world's major health challenges.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772624454390 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Arbutus Biopharma is a biotech company focused on developing a cure for hepatitis B. Its value depends on progress in clinical trials and potential scientific breakthroughs. General economic trends, which can be seen in this chart, do not directly impact its core business.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624454413 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Arbutus Biopharma
Arbutus Biopharma is a biotech company focused on developing a drug to treat chronic hepatitis B. This chart reflects investor hopes for a breakthrough drug. Its high value, despite minimal revenue, is based on the potential market size and the success of the company's clinical programs.
P/S market segment - Pharma liver
Arbutus Biopharma is a biopharmaceutical company focused on developing drugs to treat chronic hepatitis B. Future revenue depends on the success of its clinical programs. This pharma chart compares investor expectations for Arbutus's scientific platform with those of other companies working to develop a cure for this common disease.
P/S of the market as a whole
Arbutus Biopharma is a biotechnology company focused on developing drugs for the treatment of chronic hepatitis B. The company also holds important patents for RNA drug delivery technology. This market revenue valuation chart helps understand how investors view both the company's scientific potential and the value of its intellectual property.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Arbutus Biopharma
Arbutus Biopharma is a biopharmaceutical company focused on developing a cure for chronic hepatitis B. Its future depends on the success of clinical trials. This chart shows how investors evaluate the company's scientific potential, betting that its drugs will change the treatment paradigm for this disease.
%20P%2FS%20Arbutus%20Biopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Arbutus-Biopharma&v=1772624454668 "The graph of the company's future (projected) P/S Arbutus Biopharma")
Future (projected) P/S of the market segment - Pharma liver
Arbutus Biopharma is a biotech company focused on developing a treatment for chronic hepatitis B. It also holds important patents for RNA drug delivery technology, which has led to legal disputes with Moderna. The company's valuation reflects both the potential of its own drugs and potential royalties from patent disputes.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772624454738 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Arbutus Biopharma is a biotech company focused on treating hepatitis B. Its value is based on the potential of its scientific developments. In the overall revenue growth picture illustrated by the chart, Arbutus represents a long-term bet on a scientific breakthrough in the treatment of chronic viral infections.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624454838 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Arbutus Biopharma
Arbutus Biopharma is a biotech company focused on treating hepatitis B. Its primary revenue, reflected in this chart, comes not from its own products but from royalties from Alnylam Pharmaceuticals for the use of its drug delivery technology in Onpattro.
Sales of companies in the market segment - Pharma liver
Arbutus Biopharma (ABUS) is a biopharmaceutical company focused entirely on developing a treatment for chronic hepatitis B. It uses several approaches, including RNA interference, to combat the virus. This chart shows revenue in the pharmaceuticals sector, where Arbutus is working to address one of the global health challenges.
Overall market sales
Arbutus Biopharma is a biotech company focused on developing a cure for chronic hepatitis B. Its success depends on the results of clinical trials. However, the overall economic situation, reflected in this chart, influences global healthcare spending. A strong economy allows countries to allocate more resources to combat these diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Arbutus Biopharma
Arbutus Biopharma is a biotechnology company focused on developing a treatment for chronic hepatitis B. Its future revenue depends on the success of clinical trials and partnerships. This graph reflects analyst expectations, which are essentially an assessment of the scientific potential of its developments and the enormous commercial potential if successful.
%20sales%20of%20the%20company%20Arbutus%20Biopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Arbutus-Biopharma&v=1772624455179 "Schedule of future (projected) sales of the company Arbutus Biopharma")
Future (projected) sales of companies in the market segment - Pharma liver
Arbutus Biopharma is a biopharmaceutical company focused on developing a treatment for chronic hepatitis B. The forecast on this chart reflects potential future revenue from their pipeline of drugs and licensing agreements. This is an analyst's view of the commercial prospects of their research and development pipeline.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772624455276 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
Arbutus Biopharma is a biopharmaceutical company focused on developing a treatment for chronic hepatitis B. Its value is based on the potential of its scientific platform and patent portfolio. This chart, reflecting investor sentiment in the biotech sector, influences the company's ability to attract funding to continue its research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624455346 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Arbutus Biopharma
Arbutus Biopharma is a biotechnology company focused on developing a cure for chronic hepatitis B. Its financial performance reflects significant investments in research and development. The chart shows current profitability on the path to developing a potentially revolutionary drug, the success of which will determine future profitability.
Market segment marginality - Pharma liver
Arbutus Biopharma is a biotechnology company focused on developing drugs for the treatment of chronic hepatitis B. This chart reflects its operating expenses during the research and development phase. The company's future profitability is entirely dependent on the success of its clinical programs and the potential development of a functional cure for hepatitis B.
Market marginality as a whole
Arbutus Biopharma is a biotech company focused on developing a cure for hepatitis B. Its market capitalization depends on progress in clinical trials. This total return chart reflects investors' risk appetite. A favorable economic environment makes it easier to attract funding for the long-term, capital-intensive research Arbutus is conducting.
Employees in the company, segment and market as a whole
Number of employees in the company Arbutus Biopharma
Arbutus Biopharma is a biotech company focused on developing a cure for chronic hepatitis B. Its small but dedicated team consists of leading scientists in the field. Growth on this graph will indicate progress in clinical trials and progress toward the goal of a functional cure.
Share of the company's employees Arbutus Biopharma within the market segment - Pharma liver
Arbutus Biopharma is a biotechnology company fully focused on developing a cure for chronic hepatitis B. Its main asset during the research and development phase is its scientific team. This chart shows the company's human resources dedicated to combating one of the most common chronic viral diseases in the world.
Number of employees in the market segment - Pharma liver
Arbutus Biopharma is focused on developing a treatment for chronic hepatitis B. The employment dynamics in the liver disease pharmaceutical sector, visible in the graph, reflect the scientific activity in this field. For Arbutus, the growing number of researchers signifies both progress in understanding the virus and the emergence of competitive approaches to its treatment.
Number of employees in the market as a whole
Arbutus Biopharma is a biopharmaceutical company focused on developing a cure for hepatitis B. Its staff consists of highly specialized scientists. The company's growth is driven by clinical progress and funding, rather than the economic cycles depicted here, as it works to address a global health problem.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Arbutus Biopharma (ABUS)
Arbutus Biopharma is a biopharmaceutical company focused on developing a cure for chronic hepatitis B. Its entire capital comes from research and development (R&D) and patents. This metric reflects how the market evaluates the potential of its scientific platform. This enormous value is generated by a small team of highly qualified scientists.
%20of%20the%20company%20Arbutus%20Biopharma%20(ABUS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Arbutus-Biopharma-ABUS&v=1772624455520 "Chart of market capitalization per employee (in thousands of dollars) of the company Arbutus Biopharma (ABUS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Arbutus Biopharma is working on a cure for chronic hepatitis B. In biotech, market capitalization reflects the hope for a scientific breakthrough. This chart shows the enormous future value the market places on the work of each company scientist, who could contribute to curing millions of people.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772624455550 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Arbutus Biopharma is a biotech company focused on developing a drug to treat chronic hepatitis B. The chart reflects the company's scientific potential. The company's entire value is derived from the hopes it has for its developments. This indicator demonstrates the value the market places on the research and expertise of each scientist on the team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624455797 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Arbutus Biopharma (ABUS)
Arbutus Biopharma is a biotech company focused on treating hepatitis B and Covid-19. The company is in the R&D stage. This graph likely shows negative profit per employee (i.e., a loss). It reflects how much the company is investing in each of its scientists in the hopes of creating a breakthrough treatment.
%20Chart%20Arbutus%20Biopharma%20(ABUS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Arbutus-Biopharma-ABUS&v=1772624455826 "Company Profit Per Employee (in thousands of dollars) Chart Arbutus Biopharma (ABUS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Arbutus Biopharma is a biotechnology company focused on developing a cure for chronic hepatitis B. It is a clinical-stage R&D company. This metric (loss per employee) reflects the cost of years of research and testing in pursuit of a breakthrough drug.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772624455857 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Arbutus Biopharma is a biotech company focused on developing a drug to treat chronic hepatitis B. It is a clinical-stage R&D company. It is not profitable. Its entire staff consists of scientists. This chart is important to understand that in the viral diseases sector, an employee's value is measured not by current profits, but by the potential to create a blockbuster drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624455866 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Arbutus Biopharma (ABUS)
Arbutus Biopharma is a biotech company focused on developing a cure for chronic hepatitis B. Its revenue per employee comes from royalties from licensing its drug delivery technologies. The chart shows this passive income, which helps fund its core, but riskier, R&D activities.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Arbutus-Biopharma-ABUS&v=1772624455906 "Sales chart per company employee Arbutus Biopharma (ABUS)")
Sales per employee in the market segment - Pharma liver
Arbutus Biopharma (ABUS) is a biotech company focused on developing drugs to treat chronic hepatitis B (HBV). This chart shows the average revenue per employee in the sector. For a company in the R&D stage, this is important for assessing the efficiency of capital and personnel utilization compared to other biotech firms.
Sales per employee for the market as a whole
Arbutus Biopharma (ABUS) is a biotechnology company focused on developing drugs for the treatment of chronic hepatitis B. It also holds important patents for its mRNA delivery technology (LNP), which it licenses to other companies. This metric reflects the revenue from these licenses (royalties) per staff of scientists who continue to conduct R&D in the field of hepatitis B.
Short shares by company, segment and market as a whole
Shares shorted by company Arbutus Biopharma (ABUS)
Arbutus Biopharma (ABUS) is a biotech company specializing in the treatment of chronic hepatitis B (HBV). It's a complex problem that many are grappling with. This chart shows bearish sentiment. The high short interest reflects investor doubts that Arbutus's approach will be successful and concerns about the patent litigation the company is frequently embroiled in. (339)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Arbutus-Biopharma-ABUS&v=1772624455958 "Short Shares Chart for the Company Arbutus Biopharma (ABUS)")
Shares shorted by market segment - Pharma liver
Arbutus is a biotech company focused on developing a "functional" cure for hepatitis B. This chart reflects the overall sentiment in the sector. It reflects investor skepticism toward biotech companies working on complex viral diseases.
Shares shorted by the overall market
Arbutus Biopharma (ABUS) is a biotech company engaged in a years-long battle to develop a cure for chronic hepatitis B (HBV). It's a daunting task. This chart reflects investor fatigue and skepticism. They're betting the company will never develop an effective treatment, or that its RNA drug delivery technologies (which are licensed to other companies) won't generate the expected profits.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Arbutus Biopharma (ABUS)
Arbutus Biopharma is a biotech company working on a cure for hepatitis B. It is also known for its patents on lipid nanoparticles (LNPs), which are used in mRNA vaccines (Pfizer/Moderna). This chart measures when the stock is "overbought" on news of legal victories or "oversold" on R&D setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Arbutus-Biopharma-ABUS&v=1772624456022 "RSI 14 indicator chart for the company's stock Arbutus Biopharma (ABUS)")
RSI 14 Market Segment - Pharma liver
Arbutus Biopharma is a biotech company focused on developing drugs to treat chronic hepatitis B (HBV). They also hold important patents on mRNA delivery systems. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Arbutus compares to that.
RSI 14 for the overall market
Arbutus Biopharma (ABUS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ABUS (Arbutus Biopharma)
Arbutus Biopharma (ABUS) is a biotech company focused on developing drugs to treat chronic hepatitis B. This chart shows the average target price. It reflects analysts' opinions on the potential of their developments and clinical trial data, which are key to their valuation.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ABUS-Arbutus-Biopharma&v=1772624456163 "A chart showing analyst consensus forecasts for the expected stock price. ABUS (Arbutus Biopharma)")
The difference between the consensus estimate and the actual stock price ABUS (Arbutus Biopharma)
Arbutus Biopharma is a biotech company focused on developing a cure for chronic hepatitis B. This chart shows the gap between the market's current valuation of ABUS and analysts' perceptions of its value. This reflects their opinion of the company's chances of success in this complex but vast market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ABUS-Arbutus-Biopharma&v=1772624456210 "A chart showing the difference between the consensus forecast and the actual stock price. ABUS (Arbutus Biopharma)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Arbutus Biopharma is a biotech company pursuing the "holy grail": a functional cure for hepatitis B (HBV). It also holds patents for the lipid delivery technology used in mRNA vaccines. This chart shows analysts' overall expectations for the liver pharma sector, reflecting whether experts believe a breakthrough in HBV treatment is possible.
Analysts' consensus forecast for the overall market share price
Arbutus Biopharma is a biotech company focused on treating hepatitis B (HBV). They also hold important patents on the LNP delivery system used in mRNA vaccines (Pfizer/Moderna). This chart shows overall market sentiment. For Arbutus, whose business involves both science and patent litigation, it's important to understand how risk appetite (sentiment) influences their valuation. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Arbutus Biopharma
Arbutus Biopharma (ABUS) is a biotech company waging a holy war to develop a functional cure for Hepatitis B. But their second pillar is their patent portfolio for lipid nanoparticle (LNP) delivery technology, which is used in mRNA vaccines (Pfizer/Moderna). This chart is a hybrid. It weighs their R&D bet on Hepatitis B against their legal battle (royalties) for LNP.
AKIMA Market Segment Index - Pharma liver
Arbutus (ABUS) is a clinical-stage biotech focused on treating Hepatitis B (HBV); the company is also known for holding key patents on lipid delivery technology (LNP) used in mRNA vaccines (and is in litigation with Moderna). This summary metric measures R&D. The graph shows the segment average. This is a benchmark: how does this dual (R&D + patents) model (ABUS) differentiate it from the average pharma company?
The AKIM Index for the overall market
Arbutus Biopharma is a virology company developing a treatment for hepatitis B (HBV) and holds patents for LNP delivery (in dispute with Moderna). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific and patent history compares to the overall economic trends affecting biotech.
